Has the longest half-life period among all oral cephalosporins, the highest activity against basic pathogens of urogenital infection and higher clinical and microbiological efficacy than ciprofloxacin.
Is significantly less accompanied by the development of ADR's as compared to amoxicillin/clavulanate.
Is a good choice for successful clinical response in community acquired infections such as acute otitis media (AOM), Lower respiratory tract infections (LRTI) and urinary tract infections (UTI).
Shows better pharmacodynamic parameters than other 3rd and 2nd generation cephalosporins like cefpodoxime and cefuroxime.